Ocuphire Pharma Inc R3X1-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 8:05 AM CEST
1.79quote price arrow up+0.03 (+1.59%)
52 week range
1.39 - 6.01
Loading...
  • Open1.79
  • Day High1.79
  • Day Low1.79
  • Prev Close1.76
  • 52 Week High6.01
  • 52 Week High Date05/11/23
  • 52 Week Low1.39
  • 52 Week Low Date04/24/24

Key Stats

  • Market Cap50.96M
  • Shares Out25.61M
  • 10 Day Average Volume2.78
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-35.84

KEY STATS

  • Open1.79
  • Day High1.79
  • Day Low1.79
  • Prev Close1.76
  • 52 Week High6.01
  • 52 Week High Date05/11/23
  • 52 Week Low1.39
  • 52 Week Low Date04/24/24
  • Market Cap50.96M
  • Shares Out25.61M
  • 10 Day Average Volume2.78
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-35.84

RATIOS/PROFITABILITY

  • EPS (TTM)-0.43
  • P/E (TTM)-4.16
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ocuphire Pharma Inc

 

Profile

MORE
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth...
Cam Gallagher
Independent Chairman of the Board
George Magrath
Chief Executive Officer, Director
Joseph Schachle
Chief Operating Officer
Nirav Jhaveri
Chief Financial Officer, Principal Financial Officer
Address
37000 Grand River Ave., Suite 120
Farmington Hills, MI
48335
United States